A University of Oxford study of 275,000 patients found that tracking trends in 23 routine blood tests over time improved cancer risk prediction in those with unexplained weight loss, compared to single test results.
Read More
bioAffinity Technologies has received a Hong Kong patent for its CyPath Lung diagnostic platform, expanding intellectual property protection for its noninvasive lung cancer detection technology in the Asian market.
Read More
VolitionRx reported 95% detection of early-stage solid cancers in blinded validation of its CTCF-protected ctDNA Capture-Seq liquid biopsy, according to data presented at the ESMO MAP Conference.
Read More
AI models analyzing routine H&E slides can identify genomic alterations and immune patterns in NSCLC, supporting biomarker discovery and patient stratification, according to studies to be presented by Lunit at WCLC 2026.
Read More
BillionToOne has launched Northstar Origin, a liquid biopsy add-on that predicts cancer tissue of origin from cell-free DNA, and expands its genomic profiling panel to 102 genes.
Read More